Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma

Figure 3

CT imaging after nivolumab/ipilimumab treatment: (a) axial imaging demonstrating significant decrease in size of the renal mass; (b) coronal imaging demonstrating resolution of the bulky retroperitoneal lymphadenopathy.

(a)

(b)